Functional gastrointestinal disorders: a review of the main provisions of the Rome IV consensus


Objectives - the review presents the analysis of the main changes in Rome IV. The subsequent Rome IV consensus focused on the etiology, pathogenesis, diagnosis and differential diagnosis of the functional gastrointestinal disorders. It updated some definitions of the functional gastrointestinal disorders; opioid-induced constipation was set as a separate disorder; functional abdominal distention was considered specific for functional abdominal bloating as both disorders are often combined and do not replace each other. The functional gastrointestinal disorders still remain of the high medico-social importance as they are endemic, refractory and cause long-term disability.

Conflict of Interest: nothing to disclose.

Список литературы

1.Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology.2016;150(6):1393–1407. doi: 10.1053/j.gastro.2016.02.031

2. Lowell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin. Gastroenterol. 2012; 10: 712–721. doi: 10.1016/j.cgh.2012.02.029

3. Palson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am. J. Gastroenterol.2014 Sep;109(9):1450–60. doi: 10.1038/ajg.2014.181

4. Patel P, Bercik P, Morgan DG, et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand. J. Gastroenterol.2015;50:816–823. doi: 10.3109/00365521.2015.1007079

5. Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol.2015 Mar;110(3):444–54. doi: 10.1038/ajg.2015.6

6. Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399–1407.e2. doi: 10.1053/j.gastro.2015.07.054

7. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 pluselectrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am. J. Gastroenterol. 2013;108:1508–1515. doi: 10.1038/ajg.2013.197

8. Portila M, Prieto B, Shailubhai K, et al. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. Am. J. Gastroenterol.2017 Apr;112(4):613–621. doi: 10.1038/ajg.2016.611

9. Bajor A, Tornblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant risk factor for symptoms and treatment in IBS. Gut.2015;64:84–92. doi: 10.1136/gutjnl-2013-305965

10. Ford AC, Moayyedi P, Lacy BE, et al. Quigley E.M. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am. J. Gastroenterol.2014;109(1):S2–S26. doi: 10.1038/ajg.2014.187

11. Lembo APimentel MRao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology.2016 Dec;151(6):1113–1121. doi: 10.1053/j.gastro.2016.08.003

12. Manheimer E, Wieland LS, Cheng K, et al. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol.2012;107:835–847. doi: 10.1038/ajg.2012.66

13. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J. Gastroenterol.2010;16:69–75. doi: 10.3748/wjg.v16.i1.69

14. Chang FY, Chen PH, Wu TC, et al. Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac. J. Clin. Nutr.2012;21:594–600.

15. Porter CK, Gormley R, Tribble DR, et al. The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am. J. Gastroenterol.2011;106:130–138. doi: 10.1038/ajg.2010.371

16. Zhu Y, Zheng X, Cong Y, Chu H, et al. Bloating and distention in irritable bowel syndrome: the role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency. Am. J. Gastroenterol.2013; 108:1516–1525. doi: 10.1038/ajg.2013.198

17. Jiang X, Locke GR, Choung RS, et al. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut.2008;57:756–763. doi: 10.1136/gut.2007.142810

18. Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioidinduced constipation: a systematic review. J. Clin. Gastroenterol.2015;49:9–16. doi: 10.1097/MCG.0000000000000246

19. Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin. J. Pain.2019 Feb;35(2):174–188. doi: 10.1097/AJP.0000000000000662

Для цитирования

Osadchuk AM, DavydkinIL, Gritsenko TA, Kurtov IV. Functional intestinal disorders: a review of the main provisions of IV Roma consensusScience & Innovations in Medicine.2019;4(2):9-15.DOI: 10.35693/2500-1388-2019-4-2-9-15


Send an online application form to the publication